Data Substantiates Company's Position as a
Global Leader In Health Care Solutions
Key findings in the study include:
- 9 out of 10 patients reported some degree of improvement of
their chronic pain.
- 7 out of 10 reported an improvement larger than 50% after 4
weeks of treatment.
- 7 out of 10 patients did not experience any adverse effects
related to the treatment. Reported adverse side effects were mild
and transient, fading after 12 weeks.
TORONTO, April 5,
2022 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), the global
medical cannabis leader expanding throughout Latin America and Europe, has published in the international
peer-reviewed journal Frontiers in Pain Research the results
of its first clinical study on the use of medical cannabis
prescribed to Colombian patients in treating chronic pain.
This is the largest study of its kind in Latin America, and the first published
clinical evidence on the effectiveness and safety of Khiron's THC
and CBD oil-based cannabis formulations, the two most prescribed
products at Khiron's Zerenia Clinics in Colombia. This is reassuring data for
prescribing physicians and health insurance providers on the
efficacy, safety, and cost-effectiveness of the Khiron's products
to treat chronic pain. Frontiers journals rank among the most
influential in their academic fields based on total citations and
ranks as the 3rd most-cited publisher among the 20 largest
publishers.
The study, a joint effort by medical researchers from Khiron
Life Sciences and doctors from Zerenia Clinics in Colombia and Europe, captures patient-reported outcome
measures ("PROMS") and adverse effects in a large cohort of 2112
adult patients diagnosed with chronic pain of diverse etiology.
Between May and September 2021,
patients received adjuvant treatment with Khiron's oral oil-based
cannabis formulations at the Latin American Institute of Neurology
and Nervous System (ILANS-Zerenia) in Bogotá, Colombia.
"This study, based on Khiron's medical products, is critical to
reassure physicians and health insurance providers of the efficacy
of medicinal cannabis to treat chronic pain. The global impact and
economic burden of chronic pain in our society, mounting medical
evidence will increase access to cannabinoid-based medicines
worldwide." says Alvaro Torres,
Khiron CEO and Director. "The recent vote in the US House of
Representatives promoting medical research on cannabis clearly
shows the pressing need to develop effective and safe
cannabis-based medication for suffering patients worldwide. With
this and upcoming studies, Khiron will continue to stand above in
the field of medical research and to expand the access for patients
in those jurisdictions in which we are present".
Guillermo Moreno-Sanz, the first
author of the study and Global Scientific Director of Khiron Life
Sciences adds, "We believe these findings to be generalizable
across patient populations, considering that our results are
extremely well-aligned with those reported by researchers working
with similar clinical populations in nations with long-standing
medicinal cannabis access programs, such as Israel and Canada."
This study is groundbreaking for Khiron as most observational
and experimental studies investigating the efficacy of medical
cannabis for pain management are of relatively short duration and
use a disparity of cannabinoid-based products, routes of
administration, and dosing regimens. This study is differentiated
as it describes the short-, mid- and long-term efficacy and safety
of two monovarietal formulations containing THC and CBD in
different ratios (1:1 and 1:25, respectively), and investigates the
contribution of patient's sex, and age. Most participants were
female (76.1%) with an average age of 58.7 years old. One third of
the participants were elderly (>65 years old).
As Khiron continues to expand its research and business globally
through Latin America and
Europe, additional studies are
expected to continue to demonstrate the Company's business model,
creating a 360-solution for health care providers, insurance
companies, and patients to benefit from the prescription and
positive health outcomes from medical cannabis.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated international medical cannabis company with
core operations in Latin America
and Europe. Leveraging
wholly-owned medical health clinics and proprietary telemedicine
platforms, Khiron combines a patient-oriented approach, physician
education programs, scientific expertise, product innovation, and
agricultural infrastructure to drive prescriptions and brand
loyalty with patients worldwide. The Company has a sales presence
in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leading-global-medical-cannabis-company-khiron-publishes-clinical-study-on-the-effectiveness-of-its-products-at-controlling-chronic-pain-301517698.html
SOURCE Khiron Life Sciences Corp.